1. Optimizing Deep Molecular Responses in Patients With Newly Diagnosed CML

2. The Changing Goals of CML Therapy

3. Considerations in Selecting a First-Line Treatment Option

4. Molecular Response With Second-Generation TKI in Higher Risk Patients

5. Long-Term Outcomes With Second-Generation TKI in Higher Risk Patients

6. Sustained Molecular Response With Second-Generation TKI

7. The Value of TFR as a Goal in CML

8. TFR Proof of Concept: STIM

9. STIM: Long-Term Follow-Up

10. Criteria for Restarting Treatment: A-STIM vs STIM

11. EURO-SKI: Sustained MMR After TKI Discontinuation

12. EURO-SKI: Identifying Prognostic Factors

13. Discontinuing Second-Generation TKI: STOP 2G-TKI

14. Discontinuing Second-Generation TKI: DADI

15. Discontinuing Second-Generation TKI: ENESTfreedom

16. Discontinuing Second-Generation TKI: ENESTop

17. ENESTop: Subgroup Analysis

18. Monitoring Response to First-Line TKI: ELN Recommendations

19. Optimizing Outcomes: Adherence, Monitoring, and Achieving Molecular Response

20. Long-Term Monitoring and Considerations for TKI Discontinuation

21. Molecular Monitoring After TKI Discontinuation

22. Anticipating and Managing AEs With TKIs

23. Management Considerations After TKI Discontinuation

24. Conclusions

25. Abbreviations

26. Abbreviations (cont)